SUBSCRIBE
SUBSCRIBE
News   Drug Development

Amgen’s Enbrel in Kids “Concerning” Say FDA Staff

June 16, 2008 | 
1 min read
WASHINGTON (Reuters) - Post-marketing reports of life-threatening complications in children given Amgen Inc's drug Enbrel for psoriasis are 'concerning,' U.S. Food and Drug Administration staff said in documents released on Monday.
Clinical research Postmarket research
Amgen Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Insights
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
February 26, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker
Close up shot of the dart arrow hit on bulleyes of dartboard to represent that the business reached the target with dark tone picture style. Target and goal as concept.
Diabetes
Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front
February 26, 2026
 · 
2 min read
 · 
Annalee Armstrong
Working man icon pushing the load on the line. Hard work, labor, effort and determination concept.
HIV
Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data
February 26, 2026
 · 
2 min read
 · 
Tristan Manalac
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
Regulatory
Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study
February 25, 2026
 · 
2 min read
 · 
Tristan Manalac